Trial Profile

A Phase 1, Open-Label, Fixed Sequence Drug Interaction Study to Evaluate the Potential Intestinal Inhibitory Effect of Quizartinib on the Pharmacokinetics of a Pgp Substrate Dabigatran Etexilate in Healthy Subjects

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabigatran etexilate (Primary) ; Quizartinib (Primary)
Indications Acute myeloid leukaemia; Cardiomyopathies; Cardiovascular disorders; Deep vein thrombosis; Gastrointestinal haemorrhage; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Pulmonary embolism; Stroke; Vascular disorders; Venous thromboembolism
Focus Pharmacokinetics
Sponsors Daiichi Sankyo Company

24 Mar 2023 Results presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
14 Apr 2021 Status changed from active, no longer recruiting to completed.
01 Oct 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com